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Summary A study was made of the incidence of p53 mutations in Japanese males with prostate cancer or
benign prostatic hyperplasia. Polymerase chain reaction single-strand conformation polymorphism (PCR-
SSCP) was used as a primary screening technique with gene sequencing being carried out in positive cases.
Two out of 21 prostate cancers (9.5%) were found to have p53 mutations. These were stage B2 and D2
prostate cancers. No abnormalities were found in the remaining cases or benign prostatic hyperplasia.
Mutations of the p53 gene would thus appear infrequent in the tumourigenesis of primary prostate
cancer.
Prostatic adenocarcinoma is the fourth and second most
common cause of cancer death among men in the UK
(Davies & Eaton, 1991) and United States (Silverberg et al.,
1990), respectively. Recent reports in Japan demonstrated
steady increase in the clinical incidence of this neoplasm. It is
now the most frequently encountered urologic tumour in
Japan (Jap. Health Welfare Statistics Assoc. 1991). Wide
geographic and racial variations in the incidence of clinically
diagnosed prostate cancer has been demonstrated between
western countries and Japan. The prevalence ranges from
5.1-8.8 cases/100,000 population in Japan to 41.7-91.2
cases/100,000 in the United States (Waterhouse et al.,
1982).
Recent advances in molecular genetics of other prevalent
tumours, such as colorectal (Vogelstein et al., 1988), bladder
(Tsai et al., 1990), lung (Weston et al., 1989) and breast
cancers (Callahan & Cambell, 1989), indicate multiple genetic
alterations by activation of oncogenes (see Bishop, 1991 for
reviews) and, more importantly, the inactivation of tumour
suppressor genes (see Marshall, 1991 for reviews) is closely
related to pathogenesis of these malignancies.
However, the genetic targets of tumour suppressor genes in
prostate cancer and benign prostatic hyperplasia have yet to
be adequately characterised. Previous studies on primary pro-
state cancer demonstrate the allelic loss of chromosome 17p
by RFLP analysis to occur in approximately one-fifth of
clinically resected tumours. Thus, inactivation of tumour sup-
pressor genes including p53 gene may importantly be involv-
ed in human prostate carcinogenesis (Carter et al., 1990c).
This paper reports the incidence of p53 gene mutations in
21 human prostate cancers and 19 benign prostatic hyper-
plasia in Japanese patients. Polymerase chain reaction single-
strand conformation polymorphism (PCR-SSCP) was used as
a primary screening technique with gene sequencing being
carried out in positive cases.
Materials and methods
Samples and DNA extraction
The human prostate cancer cell lines, PC-3 (Kaighn et al.,
1979) and DU-145 (Stone et al., 1978), were obtained from
the American Tissue Type Collection and used as positive
controls. In PC-3, a C deletion at codon 138 on exon 5 of the
p53 gene and a point mutation at codon 223 on exon 6 and
codon 274 on exon 8 in DU-145 have been reported by
Isaacs et al. (1991). The human lung cancer cell line, KTA-7
(Kasai et al., 1991), was cultured in serum free medium,
ACL-3, and had a point mutation on exon 5 of the p53 gene
(Wada et al., submitted for publication). These three cancer
cell lines were used as positive controls in PCR-SSCP
analysis. Peripheral blood leukocyte DNA from a young
healthy adult was served as the negative control.
Tissues from 21 primary prostate cancers and 19 benign
prostatic hyperplasia were analysed. Samples of prostate
cancers were obtained by radical prostatectomy (10), by
radical cystoprostatectomy (1) and by transurethral resection
(10). In order to improve the sensitivity of the detection of
p53 gene mutations, sequential frozen section were mounted
on glass slides, stained, and evaluated microscopically to
select area that preferentially contained more tumour and
fewer contaminating nontumour cells. In all samples, areas of
tumour involvement more than 80% on histological sections
were selected for analysis. Nineteen samples of benign pros-
tatic hyperplasia were obtained by transurethral resection.
All specimens were staged and graded according to the
General Rule for Clinical and Pathological Studies on Pros-
tatic Cancer (Jap. Urol. Assoc. and Pathol. Soc., 1992),
adopted from the staging system of the American Joint Com-
mission on Cancer (MacCullough, 1988). Stage A is defined
as malignant disease detected by pathologic examination of
tissues removed from patients with clinically benign gland.
Stage B refers to clinically detected diseases that are intracap-
sular. Stage B1 generally refers to diseases involving less than
one lobe and Stage B2, to lesions involving more than one
lobe. Stage C refers to invasion through the capsule often
extending into the seminal vesicles, Stage DI to local nodal
involvement and Stage D2, to distant nodal, bony, or visceral
metastases. Twenty specimens were classified as adenocar-
cinoma and one, mucinous adenocarcinoma. Two specimens
were classified as well differentiated, 12 moderately differ-
entiated and seven, poorly differentiated adenocarcinomas.
Three cases were classified as a Stage A, three Stage B2, two
Stage C2, four Stage D1 and nine, Stage D2. Fifteen out of
19 benign prostatic hyperplasias were classified as adeno-
myomatous, three, fibromuscular and one, as a mixture of
adenomyomatous and fibromuscular types.
Tissues were frozen in liquid nitrogen and stored at
- 80C. Genomic DNA was extracted from surgical speci-
mens, tissue cell lines and peripheral blood leukocytes from
healthy adults as a control by Proteinase K digestion and
phenol/chloroform extraction, following the method of Herr-
mann (Herrmann & Frishhauf, 1987).
PCR
Oligonucleotides as primers for PCR were synthesised on an
Applied Biosystems model 381A synthesiser based on the
published p53 gene sequence in each region from exons 5 to 8
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(Hsu et al., 1991). The designations and sequence in each
primer are as follows:
PX5LT,TGTTCACTTGTGCCCTGACT
PX6LT,TGGTTGCCCAGGGTCCCCAG
PX7LT,C-1GCCACAGGTCTCCCCAA
PX8LT,TTGGGAGTAGATGGAGCCT
SX5LT,TTCAACTCTGTCTCCTrCCT
SX6LT,GCCTCTGATTCCTCACTGA
SX7LT,AGGCGCACTGGCCTCATCAA
SX8LT,TTCCTTACTGCCTCTTGCF
PX5RT,CAGCCCTGTCGTCTCTCCAG
PX6RT,GGAGGGCCACTGACAACCA
PX7RT,AGGGGTCAGCGGCAAGCAGA
PX8RT,AGTGTTAGACTGGAAAC1-TT
SX5RT,CAGCCCTGTCGTCTCTCCAG
SX6RT,TAACCCCTCCTCCCAGAGA
SX7RT,TGTGCAGGGTGGCAAGTGGC
SX8RT,AGAGCATAACTGCACCCTTGG
-5
0
L)
The number in each designation indicates the region of the
exon of the p53 gene examined by PCR-SSCP analysis. 'LT'
and 'RT' indicate primers upstream and downstream, respec-
tively, in each region and 'PX' and 'SX', the PCR and
sequence primers.
PCR-SSCP
Point mutations in the p53 gene were detected by a modified
version of PCR-SSCP method (Hayashi et al., 1989; Orita et
al., 1989). Briefly, the 5'-ends of primers (100 pmol) were
labelled with [y32P]ATP (50 pmol, 7,000 Ci mmol- ', ICN)
and polynucleotide kinase (4 u, Boehringer Mannheim) in
10 pl of 50 mM Tris-HCl, pH 8.3, 10 mM MgCI2, 5 mM DTT
at 37°C for 30 min. The PCR mixture contained 10 pmol of
each of the labelled primers, 2 nmol of each of the four
deoxynucleotides, 150 ng of genomic sample DNA, 0.6 u of
Taq-polymerase (Perkin Elmer Cetus) and 1 p1 of 10 x buffer
specified by Cetus, and distilled water to bring total volume
to 7.5 p1. The mixtures were overlaid with a drop of light
mineral oil (Sigma), placed in Program Control System PC-
700 (ASTEC) and subjected to one cycle amplification at
95°C for 3 min and 30 cycles of amplification at 95°C for
30 s, 55°C for 30 s and 72°C for 1 min. Following the last
cycle, tubes were incubated for an additional 3 min at 72°C.
Following PCR-amplification, each mixture was heated at
82°C for 3 min with 15.0 pLI of formamide dye mixture (95%
formamide: 20 mM EDTA: 0.05% xylene cyanol: 0.05%
bromophenol blue). 1.0-3.0 ILI of the preparation were subse-
quently applied to a 5% polyacrylamide gel containing 0.5 x
TBE buffer with or without 5% glycerol. Ten per glycerol
was added as necessary. Electrophoresis was performed at
40 W for 2-4 h with cooling by a fan. The gel was dried on
filter paper and exposed to Kodak XAR film at room temp-
erature for 15 min to 24 h with an intensifying screen.
Sequencing
DNAs showing amobility shift by PCR-SSCP analysis were
amplified with a specific primer mixture, loaded onto a 2%
SeaKem GTG agarose gel (TAKARA) and purified with
SUPREC-01 (TAKARA). The sequence primers (I pmol)
were end-labelled with [,y32P]ATP (7000 Ci mmol-', 10 mCi
ml', ICN) and T4 polynucleotide kinase. Sequencing reac-
tions were conducted using the ds DNA Cycle Sequencing
System (BRL) according to the manufacturer's instructions.
Results
PCR-SSCP analysis
PCR-SSCP analysis on control samples was performed for
reliability assessment of the present method. Mobility shifts
on exon 5 of the p53 gene were observed in PC-3 prostate
cancer and KTA-7 lung cancer cells (Figure la) but could be
detected in neither DU-145 nor negative control samples. In
DU-145 prostate cancer cells, mobility shifts were evident on
exon 8 (Figure b), but not on exon 6 (data not shown) and
remaining samples.
All tumour samples were simulataneously loaded onto a
gel with a negative control. Mobility shifts were recognised in
two cases (9.5%) of the 21 human prostate cancer specimens.
Mobility of the DNA fragment corresponding to exon 7
shifted in case 103 (Figure 2a), and exon 8 in case 246
Figure 1 PCR-SSCP analysis of DNAs from peripheral blood
leukocyte as a negative control and prostate cancer (PC-3 and
DU-145) and lung cancer cell (KTA-7) lines as positive controls
was conducted for reliability assessment of the method. a,
Mobility shift of DNA fragment was detected in PC-3 and KTA-
7 in exon 5 (*) but could be detected in neither DU-145 nor
negative control samples: b, Aberrant band on exon 8 identified
only in DU-145 (*). Top abscissa indicates names of cell lines.
Bands showing mobility shifts are indicated by arrows.
(Figure 2b). Both specimens had moderately differentiated
histology. Clinical stages were B2 and D2, respectively.
Mobility shift on exons 5 to 8 of the p53 gene was observed
in none of the 19 cases of benign prostatic hyperplasia.
Sequencing
To confirm the presence of mutated p53 genes and to deter-
mine types of mutation, DNA sequencing was conducted on
two clinical prostate cancer samples (Cases 103 and 246) and
aberrant mobility shifts were seen in PCR-SSCP analysis
(Table I).
The wild type sequence at codon 244 is GGC. In case 103
the sequence TGC was found. This alternation results in a
change in amino acid sequence from wild type glycine to
mutant cysteine (Figure 3a). A point mutation also occurred
in case 246 at codon 280. Instead of the wild type sequence
AGA, the sequence ACA was observed. This causes a change
in amino acid from wild type arginine to threonine (Figure
3b). In both cases with wild type sequence was also detected,
which suggests that only one allele was affected. However,
the presence of wild type might be due to normal cells such
as fibroblasts within the tumour sample.
Discussion
Prostatic adenocarcinoma is one of the most prevalent
cancers in men. Approximately 4,000 and 28,000 men die
each year in the UK (Davies & Eaton, 1991) and the United
States (Carter & Coffey, 1990), respectively. It is now the
fourth and second leading cause of cancer death among men
in both of these countries. Because of the rapid increase in
morbidity and mortality, prostate cancer has become a signi-
ficant medical problem also in Japan. (Jap. Health Welfare
Statistics Associ. 1991). However, there is still a wide geo-
graphic and racial differences in the incidence of clinically
a
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diagnosed prostate cancer up to ten times between the United
States and Japan (Yatani et al., 1989). The combined effects
of race and diet may possibly serve as a basis for predicting
some, but not all the epidemiological spectrum of a prostate
cancer (Carter et al., 1990b; Carter et al., 1992d; Anwar et
al., 1992).
The molecular mechanisms involved in prostate tumouri-
genesis remain virtually unclarified. Various abnormalities
have been reported in the molecular genetics of prostate
cancer, such as overexpression of growth factors that include
the fibroblast growth factor, transforming growth factor-1B
families, transforming growth factor-o and epidermal growth
factor (Davies & Eaton, 1991; see Thompson, 1990 for
review). Elevated activities of proto-oncogenes such as ras
and myc has also been detected in prostate cancer (Davies &
a
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Figure 2 Mutations of the p53 gene detected by PCR-SSCP
analysis in human prostate cancer samples. All tumour samples
simultaneously loaded onto a gel with negative control samples.
PCR-SSCP analysis was conducted as described in text a,
Mobility shifts of DNA fragments were identified in cases 103 on
exon 7: b, In case 246 on exon 8 of the p53 gene. No mobility
shift could be seen in the remaining tumour or negative control
samples. Top abscissa shows patient number.
Eaton, 1991; see Thompson, 1990 for reviews). Mutations of
the ras oncogene are also present (Carter et al., 1990a;
Anwar et al., 1992). The myc oncogene alone has been found
to cause hyperplastic change in prostatic epithelium, whereas
the ras + myc condition has been observed to induce predom-
inantly malignant carcinomas in the mouse prostate reconsti-
tution model (Thompson et al., 1989). Recent studies high-
light the possible role of tumour suppressor genes in the
pathogenesis of various malignant tumours (see Marshall,
1991 for reviews). Inactivation of tumour suppressor genes
by the deletion of one copy of the gene and mutational
inactivation of the other can lead to uncontrollable cellular
proliferation characteristic of cancer. The retinoblastoma
gene (Cavenee et al., 1983; Bookstein et al., 1990), Wilms's
tumour gene (Gessler et al., 1990), DCC gene (Fearon et al.,
1990), neurofibromatosis I gene (Wallace et al., 1990), and
p53 gene on chromosome 17p (Baker et al., 1989) are among
known tumour suppressor genes.
Cytogenetic analysis of prostate cancer has yet to con-
sistently show chromosomal deletions. A study of these
chromosomes indicated highest frequency of allelic deletions
resides on chromsome 8p (Bergerheim et al., 1991), followed
by lOq (Atkin & Baker, 1985; Brothman et al., 1990; Carter
et al., 1991c; Bergerheim et al., 1991) and 16q (Carter et al.,
1991c; Bergerheim 3et al., 1991). The frequent loss of
heterozygosity at loci on chromosome 17p, where the tumour
suppressor gene p53 is located, has been shown in a wide
variety of human tumours including those of colon, lung,
breast, ovary and bladder (see Hollstein et al., 1991 for
reviews; see Levine et al., 1991 for reviews). In previous
studies on primary prostate cancer, allelic loss of chromosome
17p was noted in about one-fifth of tumours, suggesting
inactivation of the p53 gene to be importantly involved in
human prostatic carcinogenesis (Carter et al., 1990c). The p53
gene was initially identified by its ability to bind the large T
antigen of the DNA virus, SV40 (Lane & Crawford, 1979). It
is considered to be essential to the regulation of cell pro-
liferation (Boyd & Barrett, 1990). Transfection studies
indicate the wild type protein is to be capable of suppressing
cell proliferation and transformation (Finlay et al., 1989;
Mercer et al., 1990). Most mutations of this gene found in a
variety of surgical specimens from malignant tumours are
clustered in the highly conserved region between amino-acid
residues 130 and 290 (Nigro et al., 1989; see Levine et al.,
1991 for reviews). These findings prompted the authors to
look for mutations of this gene in the coding region of exons
5 to 8.
Detailed information of p53 gene mutations in clinical
samples of prostate cancer are limited. In one study, one of
the two primary prostate cancers was found to possess a
point mutation (GTG-GGG) at codon 197 (Isaccs et al.,
1991). In another report, a T to C alteration at codon 172
was a feature of both the primary and metastatic tumours
common to the regional node (Effert et al., 1991). Significant
difference in the immunoreactivity of the monoclonal anti-
body toward the p53 gene product has been observed for
prostate cancer and benign prostatic hyperplasia. Five of the
29 (17%) prostate cancer specimens stained positive, but
none in the 34 samples from patients with benign prostatic
hyperplasia (Thompson et al., 1992). In our study, p53 gene
mutations were detected in only two of the 21 (9.5%) speci-
mens of prostate cancer. No specimens of benign prostatic
hyperplasia possessed a mutation of this gene. The incidence
of point mutations of this gene found in our study was
Table I p53 mutations in primary prostate cancer
Patient Histology GradeaStagea PCR-SSCP' Codon Nucleotide change Amino acid change
103 Adeno-ca mod B2 exon 7 244 GGC-T/GGC Glycine-Cysteine/Glycine
246 Adeno-ca mod D2 exon 8 280 AGA-AC/GA Arginine-Threonine/Arginine
aTumour histology, grade and stage were determined according to the criteria of the General Rule for
Clinical and Pathological studies on Prostatic Cancer (Jap. Urol. Assoc. and Pathol. Soc., 1992).
bPCR-SSCP analysis was performed from exon 5 to 8. Adeno-ca, adenocarcinoma; mod, moderately
differentiated.754 T. UCHIDA et al.
a b
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Control 103 Control 246
Figure 3 Direct-sequencing analysis of the p53 gene in human prostate cancer. a, In case 103 the sequence TGC was found. This
alternation results in a change in amino acid sequence from wild type glycine (GGC) to mutant cysteine (TGC). b, A point
mutation also occurred in case 246 at codon 280 with a change in amino acid from wild type arginine (AGA) to threonine
(ACA).
substantially less than the reported numbers of prostate
cancers with specific immunoreactivity by Thompson et al.
(1992). Difference in the sensitivity in analytical techniques
used in the studies, that is PCR-SSCP versus immunohisto-
chemical investigation, may have been the reason for this
PCR-SSCP can detect mutations if the proportion of cells
with mutated p53 gene exceeds one eighth of the total cell
population (Yamada et al., 1991). In addition, some of the
mutations in the region of the p53 gene investigated may
possibly have been overlooked. Possible explanations for
these are as follows: (a) mutations may exist in noncoding
regions of unexamined exons of the p53 gene in some
tumours since only coding exons of the p53 gene were exam-
ined (Nigro et al., 1989); (b) some p53 mutations cannot be
detected by PCR-SSCP analysis, since DNA fragments with
different sequences sometimes comigrate under certain condi-
tions (Okamoto et al., 1991). There may also exist some
disadvantages in an immunohistochemical investigation.
Assessment of positive staining is often difficult owing to its
subjective nature. Moreover, the properties of the mono-
clonal antibodies are usually the determining factor of sensi-
tivity. The PAb240 monoclonal antibody used in Thompson's
study could recognise a denaturation-resistant epitope located
between amino acids 156 and 335 (Gannon et al., 1990).
Both samples which exhibited mutant p53 gene in this
study also possessed a wild type sequence due possibly to the
intact allele in the presence of the affected allele of this gene.
Detection of a contaminant such as fibroblasts within the
tumour samples is also a possibility. The incidence of p53
gene mutations found in this study is thus probably a mini-
mal estimate. The incidence of mutations in ras families have
recently been shown to be higher in Japanese prostate
cancers than in American counterparts (Anwar et al., 1992).
It is of interest to note that the observed difference in the
incidence of p53 gene mutations might have arisen from a
variation in epidemiological factors (Carter et al., 1990b;
Anwar et al., 1992).
The incidence of mutations of the p53 gene (exons 5
through 8) has been found to be infrequent in primary
prostate cancer in Japan. No case of benign prostatic hyper-
plasia possessed mutations of this gene. Elucidation of the
role ofp53 gene mutations in metastasis and the incidence of
mutations in exons other than 5 to 8 should be carried
out.
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